Congenital Bleeding Disorders amid the COVID-19 pandemic: Open questions and recommendations.
Acta Biomed
; 91(3): e2020028, 2020 09 07.
Article
in English
| MEDLINE | ID: covidwho-761249
ABSTRACT
This article reviews the current knowledges of congenital bleeding disorders (CBD) amid the COVID-19 pandemic. It appears that CBD is not associated with higher risk of getting COVID-19 and so the prevalence of COVID-19 among them seems not higher compared to the general population. In absence of specific therapeutic recommendations, it is essential to make a correct assessment of the risk of haemorrhage/thrombosis. Based on expert opinion, strategies for outpatient management include adherence to prescribed regimens, telemedicine, and communication about COVID-19 in patients with CBD. More data should be also collected to better characterize the impact of COVID-19 on patients with CBD. The current findings encourage further studies to determine the prevalence of SARS-CoV2 infection in CBD patients to understand more fully the burden of this novel pathogen and to develop adequate preventive measures against this infection.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Telemedicine
/
Guidelines as Topic
/
Coronavirus Infections
/
Disease Management
/
Blood Coagulation Disorders, Inherited
/
Pandemics
/
Betacoronavirus
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Acta Biomed
Journal subject:
Medicine
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS